-+ 0.00%
-+ 0.00%
-+ 0.00%

Alvotech Enters Licensing, Commercialization Deal for Two Biosimilars in US, Certain Asian Markets

MT Newswires·08/21/2026 10:09:52
Listen to the news
10:09 AM EDT, 08/21/2026 (MT Newswires) -- Alvotech (ALVO.IC) and Lotus Pharmaceutical signed a licensing and commercialization agreement for two proposed biosimilars in the US and certain Asian markets, according to a Friday release. The deal covers AVT34, a planned biosimilar to AstraZeneca's (AZN.L, AZN.ST) cancer drug Imfinzi, and AVT87, a proposed biosimilar to Roche (RO.SW) units Genentech and Chugai Pharmaceutical's hemophilia A drug Hemlibra. In the US, Alvotech has the right to commercialize both products directly alongside Lotus subsidiary Alvogen. Meanwhile, Lotus will have exclusive commercialization rights in eight Asian markets, namely Hong Kong, Malaysia, the Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam.